Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples

Journal of Immunological Methods

Volumn 395, Issue 1-2, 2013, Pages 37-44

  Cludts, Isabelle ^a   Meager, Anthony ^a   Thorpe, Robin ^a   Wadhwa, Meenu ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Electrochemiluminescence; Immunogenicity; Interferon beta; Neutralizing antibodies; Non cell based assays

Indexed keywords

BETA INTERFERON; CYTOKINE RECEPTOR; NEUTRALIZING ANTIBODY;

ANTIBODY DETECTION; ARTICLE; ASSAY; BINDING AFFINITY; BINDING ASSAY; BIOLOGICAL ACTIVITY; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIPLE SCLEROSIS; NON CELL BASED ASSAY; PRIORITY JOURNAL; PROTEIN BINDING; SENSITIVITY ANALYSIS;

ANTIVIRAL ASSAY; AVA; ECL; ELECTROCHEMILUMINESCENCE; IFN-Β; IMMUNOGENICITY; INTERFERON BETA; INTERFERON-BETA; MXA; MYXOVIRUS RESISTANCE PROTEIN A; NABS; NEUTRALIZING ANTIBODIES; NON-CELL-BASED ASSAYS; RELAPSING-REMITTING MULTIPLE SCLEROSIS; REPORTER GENE ASSAY; RGA; RRMS;

ANTIBODIES, NEUTRALIZING; COHORT STUDIES; HEK293 CELLS; HUMANS; IMMUNOASSAY; INTERFERON-BETA; LUMINESCENT MEASUREMENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS;

EID: 84881550861     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2013.06.008     Document Type: Article

References (39)

1. Aarskog N.K., Marøy T., Myhr K.M., Vedeler C.A. Antibodies against interferon-beta in multiple sclerosis. J. Neuroimmunol. 2009, 212(1-2):148.
2. Alcami A., Symons J.A., Smith G.L. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J. Virol. 2000, 74(23):11230.
3. Bertolotto A. Implications of neutralizing antibodies on therapeutic efficacy. J. Neurol. Sci. 2009, 277(Suppl. 1):S29.
4. Bertolotto A., Gilli F., Sala A., Capobianco M., Malucchi S., Milano E., Melis F., Marnetto F., Lindberg R.L., Bottero R., Di Sapio A., Giordana M.T. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003, 60(4):634.
5. Bertolotto A., Sala A., Caldano M., Capobianco M., Malucchi S., Marnetto F., Gilli F. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J. Immunol. Methods 2007, 321(1-2):19.
6. Cludts I., Meager A., Thorpe R., Wadhwa W. Detection of neutralizing interleukin-17 antibodies in autoimmune polyendocrinopathy syndrome-1 (APS-1) patients using a novel non-cell-based electrochemiluminescence assay. Cytokine 2010, 50(2):129.
7. Colamonici O.R., Domanski P., Sweitzer S.M., Larner A., Buller R.M. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon α transmembrane signaling. J. Biol. Chem. 1995, 270(27):15974.
8. Daubener W., Wanagat N., Pilz K., Seghrouchni S., Fischer H.G., Hadding U. A new, simple, bioassay for human IFN-gamma. J. Immunol. Methods 1994, 168(1):39.
9. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs 2009, 23(5):379.
10. European Medicines Agency (EMEA) Guidelines on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins 2007, EMEA/CHMP/BMWP/14327/2006.
11. European Medicines Agency (EMEA) Beta-interferons and Neutralizing Antibodies (In Multiple Sclerosis) 2008, EMEA/CHMP/BWP/580136/2007.
12. European Medicines Agency (EMEA) Guidelines on Immunogenicity Assessment of Monoclonal Antibodies Intended for In Vivo Clinical Use 2012, (EMEA/CHMP/BMWP/86289/2010).
13. Farrell R.A., Espasandin M., Lakdawala N., Creeke P.I., Worthington V., Giovannoni G. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice. Mult. Scler. 2011, 17(11):1333.
14. Files J.G., Hargrove D., Delute L., Cantillon M. Measured neutralizing titers of IFN-beta neutralizing antibodies (NAbs) can depend on the preparations of IFN-beta used in the assay. J. Interferon Cytokine Res. 2007, 27(8):637.
15. Finco D., Baltrukonis D., Clements-Egan A., Delaria K., Gunn G.R., Lowe J., Maia M., Wong T. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics. J. Pharm. Biomed. Anal. 2011, 54(2):351.
16. Gneiss C., Brugger M., Millonig A., Fogdell-Hahn A., Rudzki D., Hillert J., Berger T., Reindl M., Deisenhammer F. Comparative study of four different assays for the detection of binding antibodies against interferon-beta. Mult. Scler. 2008, 14(6):830.
17. Goodin D.S. Treatment of multiple sclerosis with human beta interferon. Int. MS J. 2005, 12(3):96.
18. Grossberg S.E., Kawade Y., Kohase M., Klein J.P. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J. Interferon Cytokine Res. 2001, 21(9):743.
19. Karpusas M., Whitty A., Runkel L., Hochman P. The structure of human interferon-beta: implications for activity. Cell. Mol. Life Sci. 1998, 54(11):1203.
20. Kawade Y. Quantitation of neutralization of interferon by antibodies. Methods Enzymol. 1986, 119:558.
21. LaFleur D.W., Nardelli B., Tsareva T., Mather D., Feng P., Semenuk M., Taylor K., Buergin M., Chinchilla D., Roschke V., Chen G., Ruben S.M., Pitha P.M., Coleman T.A., Moore P.A. Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J. Biol. Chem. 2001, 276(43):39765.
22. Lallemand C., Meritet J.F., Erickson R., Grossberg S.E., Roullet E., Lyon-Caen O., Lebon P., Tovey M.G. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene. J. Interferon Cytokine Res. 2008, 28(6):393.
23. Lam R., Farrell R., Aziz T., Gibbs E., Giovannoni G., Grossberg S., Oger J. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFN-beta in multiple sclerosis patients. J. Immunol. Methods 2008, 336(2):113.
24. Meager A. Measurement of interferon activities. The Interferons: Characterization and Application 2006, 339. Wiley-VCH, Weinheim. A. Meager (Ed.).
25. Meager A., Visvalingam K., Dilger P., Bryan D., Wadhwa M. Biological activity of interleukins -28 and -29: comparison with type I interferons. Cytokine 2005, 31(2):109.
26. Meager A., Dolman C., Dilger P., Bird C., Giovannoni G., Schellekens H., Thorpe R., Wadhwa M. An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products. J. Interferon Cytokine Res. 2011, 31(4):383.
27. Moore M., Meager A., Wadhwa M., Burns C. Measurement of neutralising antibodies to type I interferons by gene expression assays specific for type 1 interferon-inducible 6-16 mRNA. J. Pharm. Biomed. Anal. 2009, 49(2):534.
28. Namaka M., Pollitt-Smith M., Gupta A., Klowak M., Vasconcelos M., Turcotte D., Gong Y., Melanson M. The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis. Curr. Med. Res. Opin. 2006, 22(2):223.
29. Pachner A.R. An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients. Neurology 2003, 61(10):1444.
30. Perini P., Calabrese M., Biasi G., Gallo P. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J. Neurol. 2004, 251(3):305.
31. Polman C.H., Bertolotto A., Deisenhammer F., Giovannoni G., Hartung H.P., Hemmer B., Killestein J., McFarland H.F., Oger J., Pachner A.R., Petkau J., Reder A.T., Reingold S.C., Schellekens H., Sørensen P.S. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010, 9(7):740.
32. Pungor E., Files J.G., Gabe J.D., Do L.T., Foley W.P., Gray J.L., Nelson J.W., Nestaas E., Taylor J.L., Grossberg S.E. A novel bioassay for the determination of neutralizing antibodies to IFN-β1b. J. Interferon Cytokine Res. 1998, 18(12):1025.
33. Ross C., Clemmesen K.M., Svenson M., Sorensen P.S., Koch-Henriksen N., Skovgaard G.L., Bendtzen K. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann. Neurol. 2000, 48(5):706.
34. Runkel L., Meier W., Pepinsky R.B., Karpusas M., Whitty A., Kimball K., Brickelmaier M., Muldowney C., Jones W., Goelz S.E. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon beta (IFN-beta). Pharm. Res. 1998, 15(4):641.
35. Scagnolari C., Duda P., Bagnato F., De Vito G., Alberelli A., Lavolpe V., Girardi E., Durastanti V., Trojano M., Kappos L., Antonelli G. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. J. Neurol. 2007, 254(5):597.
36. Sominanda A., Rot U., Suoniemi M., Deisenhammer F., Hillert J., Fogdell-Hahn A. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult. Scler. 2007, 13(2):208.
37. U.S.Department of Health and Human services, Food and Drug Administration Guidance for industry: assay development for immunogenicity testing of therapeutic proteins http://http:/www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM192750.pdf.
38. Wadhwa M., Subramanyam M., Goelz S., Goyal J., Jethwa V., Jones W., Files J.G., Kramer D., Bird C., Dilger P., Tovey M., Lallemand C., Thorpe R. Use of a standardised MxA protein measurement based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β. J. Interferon Cytokine Res 2013, (in press). 10.1089/jir.2012.0079.
39. Wadhwa M., Thorpe R. Assessment of unwanted immunogenicity. Immunogenicity of Biopharmaceuticals, "Biotechnology: pharmaceutical aspects" 2008, 57. A Series by Springer Publishing. M. van de Weert, E.H. Moller (Eds.).